

What is claimed is:

1. A method of treatment or prophylaxis of herpes simplex virus (HSV) infections in mammals, the method comprising,
administering intravenously to a mammal an effective amount of a composition comprising immunoglobulin A (IgA) prepared from pooled human plasma.
2. The method of claim 1, wherein the mammal is neonatal human.
3. The method of claim 1, wherein the mammal is immunocompromised.
4. The method of claim 1, wherein the mammal suffers from a herpetic disease.
5. The method of claim 4, wherein the disease is selected from the group consisting of encephalitis, pneumonia, hepatitis, herpes ocularis, chickenpox, shingles, zoster oticus, zoster varicellousus, keratitis, herpes digitalis, herpes facialis, herpes genitalis, herpes gladiatorum, and herpes stomatitis.
6. The method of claim 4, wherein the disease is selected from the group consisting of encephalitis, pneumonia, hepatitis, shingles, zoster oticus, and zoster varicellousus.
7. The method claim 4, wherein the disease is encephalitis.
8. The method of claim 1, wherein the IgA comprises at least from about 35% to about 55% of any immunoglobulins present in the composition.
9. The method of claim 1, wherein the IgA comprises at least from about 60% to about 80% of any immunoglobulins present in the composition.

10. A method of treatment or prophylaxis of herpes simplex virus (HSV) infections in mammals, the method comprising,
 - administering intravenously to a mammal an effective amount of a composition comprising monomeric IgA, dimeric IgA, and IgG prepared from pooled human plasma,
 - wherein monomeric and dimeric IgA comprise at least from about 35% to about 55% of the total immunoglobulins present in the composition.
11. The method of claim 10, wherein monomeric and dimeric IgA comprise at least from about 60% to about 80% of the total immunoglobulins present in the composition.
12. The method of claim 10, wherein monomeric and dimeric IgA comprise at least from about 70% to about 95% of the total immunoglobulins present in the composition.
13. The method of claim 10, wherein monomeric and dimeric IgA comprise at least about 60% of the total immunoglobulins present in the composition.
14. The method of claim 10, wherein monomeric and dimeric IgA comprise at least about 80% of the total immunoglobulins present in the composition.
15. The method of claim 10, wherein monomeric and dimeric IgA comprise at least about 90% of the total immunoglobulins present in the composition.
16. A method of treatment or prophylaxis of herpetic disease in mammals, the method comprising,
 - administering topically to a mammal an effective amount of a composition comprising immunoglobulin G (IgG) prepared from pooled human plasma.

17. The method of claim 16, wherein the herpetic disease is selected from the group consisting of chickenpox, shingles, zoster oticus, zoster varicellousus, keratitis, herpes digitalis, herpes facialis, herpes genitalis, herpes gladiatorum, and herpes stomatitis.
18. A method of treatment or prophylaxis of ocular herpetic disease in mammals, the method comprising,
 - administering topically to a mammal an effective amount of a composition comprising immunoglobulin G (IgG) prepared from pooled human plasma.
19. The method of claim 18, wherein the herpetic disease is keratitis.
20. A method of treatment or prophylaxis of ocular herpetic disease in mammals, the method comprising,
 - administering a suspension comprising an effective amount of immunoglobulin G (IgG) prepared from pooled human plasma directly to an infected eye of a mammal.